Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Turnstone Biologics Corp. ( (TSBX) ).
Turnstone Biologics Corp. announced a merger agreement that resulted in amendments to the Surviving Corporation’s certificate of incorporation and bylaws. These changes took effect immediately following the merger’s Effective Time, impacting the corporate governance structure.
The most recent analyst rating on (TSBX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Turnstone Biologics Corp. stock, see the TSBX Stock Forecast page.
Spark’s Take on TSBX Stock
According to Spark, TipRanks’ AI Analyst, TSBX is a Underperform.
TSBX is facing severe financial and operational challenges, as evidenced by declining revenues, persistent losses, and halted clinical studies. The technical indicators show a bearish trend, while the valuation suggests potential undervaluation offset by high risk. The company’s exploration of strategic alternatives may offer future opportunities but currently reflects uncertainty and instability.
To see Spark’s full report on TSBX stock, click here.
More about Turnstone Biologics Corp.
Average Trading Volume: 401,091
Technical Sentiment Signal: Sell
Current Market Cap: $8.21M
Learn more about TSBX stock on TipRanks’ Stock Analysis page.